ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association

Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA Submission

August 7, 2015 8:36 AM EDT

Needham & Company analyst Alan Carr reiterated a Buy rating and boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $49.00 (from $38.00) following Q2 results and ahead of NDA submission.

Carr commented, "Acadia hosted a quarterly conference call last night. Mgmt guided for Nuplazid NDA... More

Cowen Raises Price Target on Acadia Pharma (ACAD) Following 2Q15

August 7, 2015 6:56 AM EDT

Cowen reiterated an Outperform rating on Acadia Pharmaceuticals (NASDAQ: ACAD), and raised the price target to $50.00 (from $43.00), following 2Q15 results. ACAD reported 2Q15 EPS of $(0.39) vs consensus of $(0.33).

Analyst Ritu Baral commented, "ACAD's 2Q15 call was largely uneventful with ACAD... More